newsfilter
← Latest News
GlobeNewswire·

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025